Estimate of Increase in Colorectal Cancer Diagnoses with Expansion of Fecal Immunochemical Testing in an Urban Safety-Net Population.
Advanced adenoma
Colorectal cancer screening
Fecal immunochemical test
Prediction model
Screening
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
02 Dec 2023
02 Dec 2023
Historique:
received:
28
04
2023
accepted:
09
11
2023
medline:
2
12
2023
pubmed:
2
12
2023
entrez:
2
12
2023
Statut:
aheadofprint
Résumé
Fecal immunochemical test (FIT) is less effective in detecting advanced adenomas (AA) than colonoscopy. Increase in FIT for colorectal cancer (CRC) screening may lead to an increased number of undetected AAs which may develop into future CRCs. We determined the potential impact of FIT expansion on missed AAs and future CRC diagnoses in an urban, tertiary-care, safety-net hospital. CRC and AA diagnoses were identified in patients undergoing colonoscopy for average-risk CRC screening or positive FIT between 2017 and 2019 at Boston Medical Center. Poisson regression modeling was used to estimate the frequency of AAs per year by age group using data from 2017 to 2019, assuming average outpatient volume and proportion of screening colonoscopies. Total number of patients who received FIT was extrapolated from those who underwent colonoscopy for positive FIT. We estimated AAs per year if 'one-time' FIT was used for screening in 75% and 100% of the population and subtracted this from the estimated AAs per year under the Poisson model to determine missed AAs. We used previously described, age and gender specific estimates of the annual progression of AA to CRC. The estimated number of CRCs detected per year is 4.6/1785 males and 4.6/2086 females screened. With 75% FIT expansion, we estimate an additional 3.5 (95% CI 1.3, 9.5) and 2.2 (95% CI 0.64, 7.6) CRCs; with 100% FIT expansion, we estimate an additional 7.4 (95% CI 3.7, 14.9) and 4.2 (95% CI 1.7, 10.5) CRCs, in 5 years, in males and females, respectively. Expansion of FIT may substantially increase CRC incidence.
Sections du résumé
BACKGROUND
BACKGROUND
Fecal immunochemical test (FIT) is less effective in detecting advanced adenomas (AA) than colonoscopy. Increase in FIT for colorectal cancer (CRC) screening may lead to an increased number of undetected AAs which may develop into future CRCs.
AIM
OBJECTIVE
We determined the potential impact of FIT expansion on missed AAs and future CRC diagnoses in an urban, tertiary-care, safety-net hospital.
METHODS
METHODS
CRC and AA diagnoses were identified in patients undergoing colonoscopy for average-risk CRC screening or positive FIT between 2017 and 2019 at Boston Medical Center. Poisson regression modeling was used to estimate the frequency of AAs per year by age group using data from 2017 to 2019, assuming average outpatient volume and proportion of screening colonoscopies. Total number of patients who received FIT was extrapolated from those who underwent colonoscopy for positive FIT. We estimated AAs per year if 'one-time' FIT was used for screening in 75% and 100% of the population and subtracted this from the estimated AAs per year under the Poisson model to determine missed AAs. We used previously described, age and gender specific estimates of the annual progression of AA to CRC.
RESULTS
RESULTS
The estimated number of CRCs detected per year is 4.6/1785 males and 4.6/2086 females screened. With 75% FIT expansion, we estimate an additional 3.5 (95% CI 1.3, 9.5) and 2.2 (95% CI 0.64, 7.6) CRCs; with 100% FIT expansion, we estimate an additional 7.4 (95% CI 3.7, 14.9) and 4.2 (95% CI 1.7, 10.5) CRCs, in 5 years, in males and females, respectively.
CONCLUSION
CONCLUSIONS
Expansion of FIT may substantially increase CRC incidence.
Identifiants
pubmed: 38041763
doi: 10.1007/s10620-023-08190-y
pii: 10.1007/s10620-023-08190-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Siegel RL, Miller KD, Goding Sauer A et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70:145–164. https://doi.org/10.3322/caac.21601 .
doi: 10.3322/caac.21601
pubmed: 32133645
Davidson KW, Barry MJ, Mangione CM et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325:1965–1977. https://doi.org/10.1001/jama.2021.6238 .
doi: 10.1001/jama.2021.6238
pubmed: 34003218
Rex DK, Boland CR, Dominitz JA et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2017;112:1016–1030. https://doi.org/10.1038/ajg.2017.174 .
doi: 10.1038/ajg.2017.174
pubmed: 28555630
Robertson DJ, Lee JK, Boland CR et al. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017;152:1217-1237.e3. https://doi.org/10.1053/j.gastro.2016.08.053 .
doi: 10.1053/j.gastro.2016.08.053
pubmed: 27769517
Imperiale TF, Gruber RN, Stump TE, Emmett TW, Monahan PO. Performance characteristics of fecal immunochemical tests for colorectal cancer and advanced adenomatous polyps: a systematic review and meta-analysis. Ann Intern Med. 2019;170:319–329. https://doi.org/10.7326/M18-2390 .
doi: 10.7326/M18-2390
pubmed: 30802902
Lantinga MA, Theunissen F, Ter Borg PCJ et al. Impact of the COVID-19 pandemic on gastrointestinal endoscopy in the Netherlands: analysis of a prospective endoscopy database. Endoscopy. 2021;53:166–170. https://doi.org/10.1055/a-1272-3788 .
doi: 10.1055/a-1272-3788
pubmed: 33080630
Lui TKL, Leung K, Guo CG, Tsui VWM, Wu JT, Leung WK. Impacts of the coronavirus 2019 pandemic on gastrointestinal endoscopy volume and diagnosis of gastric and colorectal cancers: a population-based study. Gastroenterology. 2020;159:1164-1166.e3. https://doi.org/10.1053/j.gastro.2020.05.037 .
doi: 10.1053/j.gastro.2020.05.037
pubmed: 32425228
Issaka RB, Taylor P, Baxi A, Inadomi JM, Ramsey SD, Roth J. Model-based estimation of colorectal cancer screening and outcomes during the COVID-19 pandemic. JAMA Netw Open. 2021;4:e216454. https://doi.org/10.1001/jamanetworkopen.2021.6454 .
doi: 10.1001/jamanetworkopen.2021.6454
pubmed: 33843997
pmcid: 8042520
Corley DA, Sedki M, Ritzwoller DP et al. Cancer screening during the coronavirus disease-2019 pandemic: a perspective from the National Cancer Institute’s PROSPR Consortium. Gastroenterology. 2021;160:999–1002. https://doi.org/10.1053/j.gastro.2020.10.030 .
doi: 10.1053/j.gastro.2020.10.030
pubmed: 33096099
Myint A, Roh L, Yang L, Connolly L, Esrailian E, May FP. Noninvasive colorectal cancer screening tests help close screening gaps during coronavirus disease 2019 pandemic. Gastroenterology. 2021;161:712-714.e1. https://doi.org/10.1053/j.gastro.2021.04.026 .
doi: 10.1053/j.gastro.2021.04.026
pubmed: 33865840
Ahmed HS, Connolly JJ, Chung EC, Cabral HJ, Schroy PC, Mohanty A. Adaptive strategies for outpatient colonoscopies in response to COVID-19. Am J Prev Med. 2023;64:122–124. https://doi.org/10.1016/j.amepre.2022.08.002 .
doi: 10.1016/j.amepre.2022.08.002
pubmed: 36116997
Gupta S, Lieberman D, Anderson JC et al. Recommendations for follow-up after colonoscopy and polypectomy: a consensus update by the US Multi-society Task Force on Colorectal Cancer. Gastrointest Endosc. 2020;91:463-485 e5. https://doi.org/10.1016/j.gie.2020.01.014 .
doi: 10.1016/j.gie.2020.01.014
pubmed: 32044106
pmcid: 7389642
Brenner H, Altenhofen L, Stock C, Hoffmeister M. Natural history of colorectal adenomas: birth cohort analysis among 3.6 million participants of screening colonoscopy. Cancer Epidemiol Biomark Prev. 2013;22:1043–1051. https://doi.org/10.1158/1055-9965.EPI-13-0162 .
doi: 10.1158/1055-9965.EPI-13-0162
Hassan C, Piovani D, Spadaccini M et al. Variability in adenoma detection rate in control groups of randomized colonoscopy trials: a systematic review and meta-analysis. Gastrointest Endosc. 2023;97:212-225.e7. https://doi.org/10.1016/j.gie.2022.10.009 .
doi: 10.1016/j.gie.2022.10.009
pubmed: 36243103
Fisher DA, Princic N, Miller-Wilson LA, Wilson K, Fendrick AM, Limburg P. Utilization of a colorectal cancer screening test among individuals with average risk. JAMA Netw Open. 2021;4:e2122269. https://doi.org/10.1001/jamanetworkopen.2021.22269 .
doi: 10.1001/jamanetworkopen.2021.22269
pubmed: 34473259
pmcid: 8414191
Crotta S, Segnan N, Paganin S, Dagnes B, Rosset R, Senore C. High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test. Clin Gastroenterol Hepatol. 2012;10:633–638. https://doi.org/10.1016/j.cgh.2012.02.030 .
doi: 10.1016/j.cgh.2012.02.030
pubmed: 22426085
Singal AG, Corley DA, Kamineni A et al. Patterns and predictors of repeat fecal immunochemical and occult blood test screening in four large health care systems in the United States. Am J Gastroenterol. 2018;113:746–754. https://doi.org/10.1038/s41395-018-0023-x .
doi: 10.1038/s41395-018-0023-x
pubmed: 29487413
pmcid: 6476786
Mohan BP, Khan SR, Daugherty E et al. Pooled rates of adenoma detection by colonoscopy in asymptomatic average-risk individuals with positive fecal immunochemical test: a systematic review and meta-analysis. Gastrointest Endosc. 2022. https://doi.org/10.1016/j.gie.2022.04.004 .
doi: 10.1016/j.gie.2022.04.004
pubmed: 36395824
Zorzi M, Antonelli G, Barbiellini Amidei C et al. Adenoma detection rate and colorectal cancer risk in fecal immunochemical test screening programs: an observational cohort study. Ann Intern Med. 2023;176:303–310. https://doi.org/10.7326/M22-1008 .
doi: 10.7326/M22-1008
pubmed: 36802754
Bosch LJW, Melotte V, Mongera S et al. Multitarget stool DNA test performance in an average-risk colorectal cancer screening population. Am J Gastroenterol. 2019;114:1909–1918. https://doi.org/10.14309/ajg.0000000000000445 .
doi: 10.14309/ajg.0000000000000445
pubmed: 31764091
pmcid: 6903367